Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis
Recruiting
Observational Study
Rhematoid Arthritis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 – 65
- Sex
- Any
- Study type
- Observational
- Participants needed
- 110 (estimated)
- Sponsor
- Foundation University Islamabad · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent.
2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10
* Pakistani individuals
* between ages of 20-75 years
* New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available
Exclusion…
Contacts